PanLeucogated CD4 Test HIV SA: Wits Study $626M Saved | AcademicJobs
A Wits University study shows the PanLeucogated CD4 test saved $626M over 20 years, enabling massive HIV monitoring scale-up in South Africa.
No reviews yet. Be the first to rate Wendy!
Professor Wendy Stevens is a professor at the University of the Witwatersrand in the Faculty of Health Sciences, where she serves as Executive Director of the Wits Diagnostic Innovation Hub. She holds a BSc, MB BCh, and MMed from the University of the Witwatersrand. Stevens qualified as a medical doctor from Wits in 1989 with cum laude honours and later specialised in haematology, receiving a best pathology registrar award in 1995 and a distinction for her degree during specialisation.
She was appointed full professor and head of the Department of Molecular Medicine and Haematology at Wits in 2003. Stevens has led national priority programmes in partnership with the National Health Laboratory Service, contributing to the initiation of South Africa’s first HIV early infant diagnosis test, the first CD4 monitoring assay (which received FDA approval and was licensed to Beckman Coulter), national molecular HIV viral load monitoring, and GeneXpert tuberculosis diagnosis and drug resistance testing. Her work focuses on laboratory medicine, diagnostics innovation, and implementation for HIV, tuberculosis, and related areas. She has received accolades for advancing public health and maintains a prominent research profile with extensive publications in these fields.
A Wits University study shows the PanLeucogated CD4 test saved $626M over 20 years, enabling massive HIV monitoring scale-up in South Africa.